KyungdongPharm (011040) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, KyungdongPharm (011040) reported revenue of 196.3 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
2025196.3 billion KRW7.7 billion KRW8.5 billion KRW[source]
2024193.9 billion KRW2.6 billion KRW5.4 billion KRW[source]
2023162.7 billion KRW-25.0 billion KRW-20.7 billion KRW[source]
2022182.7 billion KRW8.3 billion KRW12.1 billion KRW[source]
2021177.6 billion KRW15.8 billion KRW12.6 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
2025319.2 billion KRW92.6 billion KRW226.6 billion KRW[source]
2024299.4 billion KRW82.1 billion KRW217.3 billion KRW[source]
2023291.6 billion KRW64.3 billion KRW227.4 billion KRW[source]
2022300.2 billion KRW51.6 billion KRW248.6 billion KRW[source]
2021291.0 billion KRW31.5 billion KRW259.5 billion KRW[source]

Cash Flow

YearOperatingInvestingFinancingSource
202516.9 billion KRW-1.1 billion KRW199 million KRW[source]
2024-8.1 billion KRW2.3 billion KRW9.6 billion KRW[source]
2023-32 million KRW18.7 billion KRW-21.4 billion KRW[source]
2022-1.1 billion KRW-12.6 billion KRW10.4 billion KRW[source]
202112.4 billion KRW10.7 billion KRW-21.5 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice